Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with nab-paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma.
LMB-100 is a recombinant immunotoxin (iTox) consisting of a mesothelin-binding Fab for targeting and a modified Pseudomonas exotoxin A payload. Preclinical studies showed that combining taxanes with iTox results in synergistic anti-tumor activity. The objectives of this phase I/II study were to determine the maximum tolerated dose (MTD) of LMB-100 when administered with nanoalbumin bound (nab)-paclitaxel to patients with previously treated advanced pancreatic adenocarcinoma and to assess the objective response rate. Patients (n = 20) received fixed dose nab-paclitaxel (125 mg/m2 on Days 1 & 8) with LMB-100 (65 or 100 mcg/kg on Days 1, 3 & 5) in 21-day cycles for 1-3 cycles. Fourteen patients were treated on the dose-escalation and an additional 6 in the phase II expansion. MTD of 65 mcg/kg was established for the combination. Dose-limiting toxicity (DLT) resulting from capillary leak syndrome (CLS) was seen in 2 of 5 patients treated at 100 mcg/kg and 1 of 6 evaluable phase I patients receiving the MTD. Severity of CLS was associated with increases in apoptotic circulating endothelial cells (CECs). LMB-100 exposure was unaffected by anti-LMB-100 antibody formation in 5 of 13 patients during cycle 2. Seven of 17 evaluable patients experienced >50% decrease in CA 19-9, including 3 with previous exposure to nab-paclitaxel. One patient developed an objective partial response. Patients with biomarker responses had higher tumor mesothelin expression. Although clinical activity was observed, the combination was not well tolerated and alternative drug combinations with LMB-100 will be pursued.